Financial Comparison: Venus Concept (VERO) & Its Peers
Venus Concept (NASDAQ: VERO) is one of 132 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Venus Concept to related businesses based on the strength of its risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Valuation and Earnings
This table compares Venus Concept and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Venus Concept||$21.96 million||-$28.73 million||-0.59|
|Venus Concept Competitors||$1.43 billion||$157.00 million||8.56|
This is a summary of current ratings and recommmendations for Venus Concept and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Venus Concept Competitors||1107||3554||5871||328||2.50|
Venus Concept currently has a consensus target price of $10.00, indicating a potential upside of 31.58%. As a group, “Surgical & medical instruments” companies have a potential upside of 8.90%. Given Venus Concept’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Venus Concept is more favorable than its competitors.
Risk & Volatility
Venus Concept has a beta of 3.98, meaning that its share price is 298% more volatile than the S&P 500. Comparatively, Venus Concept’s competitors have a beta of 0.93, meaning that their average share price is 7% less volatile than the S&P 500.
Insider & Institutional Ownership
8.8% of Venus Concept shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 37.8% of Venus Concept shares are owned by company insiders. Comparatively, 15.1% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Venus Concept and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Venus Concept Competitors||-568.90%||-107.04%||-23.15%|
Venus Concept beats its competitors on 7 of the 13 factors compared.
Venus Concept Company Profile
Venus Concept Inc. operates as a medical aesthetic technology company worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-treatment platform to address the aesthetic procedures without surgery or downtime; Venus Legacy, an advanced device that resolves challenging face and body aesthetic needs; Venus Velocity, a diode laser for hair removal; Venus Fiore, which addresses internal vaginal health restoration, labia skin tightening, and mons pubis reduction; Venus Viva, a customizable skin resurfacing device that allows operator control of ablation and coagulation for resolving the appearance of mild to severe skin damage for various skin types; Venus Freeze Plus, an anti-aging system for non-invasive skin tightening; and Venus Bliss, a solution for the fat reduction category. The company also offers NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process; and ARTAS and ARTAS iX robotic hair restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept Inc. is headquartered in Toronto, Canada.
Receive News & Ratings for Venus Concept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venus Concept and related companies with MarketBeat.com's FREE daily email newsletter.